Cargando…

Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis

BACKGROUND: Colorectal cancer is one of the leading causes of cancer deaths in both sexes in the world. Improvement of existing therapy modalities and implementing new ones in order to improve survival of patients with colorectal cancer represents a great challenge for medicine. The aim of this pape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ilic, Irena, Jankovic, Slobodan, Ilic, Milena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006969/ https://www.ncbi.nlm.nih.gov/pubmed/27579775 http://dx.doi.org/10.1371/journal.pone.0161912

Ejemplares similares

Colorectal cancer mortality trends in Serbia during 1991–2010: an age-period-cohort analysis and a joinpoint regression analysis
por: Ilic, Milena, et al.
Publicado: (2016)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis
por: Cao, Dedong, et al.
Publicado: (2019)

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
por: Xu, Wei, et al.
Publicado: (2016)

Association between oral contraceptive use and pancreatic cancer risk: A systematic review and meta-analysis
por: Ilic, Milena, et al.
Publicado: (2021)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: da Silva, Wânia Cristina, et al.
Publicado: (2018)

Ischaemic heart disease mortality in Serbia, 1991-2013; a joinpoint analysis
por: Ilic, Milena, et al.
Publicado: (2017)

Worldwide suicide mortality trends (2000-2019): A joinpoint regression analysis
por: Ilic, Milena, et al.
Publicado: (2022)

Cancer mortality in Serbia, 1991–2015: an age-period-cohort and joinpoint regression analysis
por: Ilic, Milena, et al.
Publicado: (2018)

Malignant Lymphatic and Hematopoietic Neoplasms Mortality in Serbia, 1991–2010: A Joinpoint Regression Analysis
por: Ilic, Milena, et al.
Publicado: (2014)

International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis
por: Ilic, Irena, et al.
Publicado: (2022)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Trends in suicide by hanging, strangulation, and suffocation in Serbia, 1991-2020: A joinpoint regression and age-period-cohort analysis
por: Ilic, Milena, et al.
Publicado: (2022)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Epidemiology of pancreatic cancer
por: Ilic, Milena, et al.
Publicado: (2016)

Epidemiology of stomach cancer
por: Ilic, Milena, et al.
Publicado: (2022)

Global Patterns of Trends in Cholera Mortality
por: Ilic, Irena, et al.
Publicado: (2023)

Diabetes Mellitus after SARS-CoV-2 Infection: An Epidemiological Review
por: Ilic, Irena, et al.
Publicado: (2023)

International patterns and trends in the brain cancer incidence and mortality: An observational study based on the global burden of disease
por: Ilic, Irena, et al.
Publicado: (2023)

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
por: LIM, SUNG HEE, et al.
Publicado: (2023)

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
por: Wu, Qian, et al.
Publicado: (2013)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
por: van Nassau, Sietske C., et al.
Publicado: (2021)

A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon
por: Temraz, Sally, et al.
Publicado: (2022)

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis
por: Koch, Christine, et al.
Publicado: (2017)

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
por: Elshenawy, Mahmoud A., et al.
Publicado: (2020)

Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2016)

Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Li, Qin, et al.
Publicado: (2015)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
por: Sun, Zhengwu, et al.
Publicado: (2020)

The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer
por: Zhao, Jiemin, et al.
Publicado: (2017)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis
por: Zhang, Chun-Jing, et al.
Publicado: (2018)

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
por: Cai, Jun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mvip0mtv5h3cagmg01qu9mkjua